2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 217-219
Technology and Procedures, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Biological Therapies, Antibody Therapy, Transplantation, Infusion, Adverse Events, Biological Processes, Hematopoiesis, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Pediatric
PAPER

873 Efficacy and safety of romiplostim N01 versus recombinant human interleukin-11 in the treatment of cancer therapy-induced thrombocytopenia: A prospective, randomized, controlled trial

Xiaofeng Chen, Chao Dong2, Dequan Ding3, Qing Guo4, Weifei Fan5, Wenbin Lu6, Jianming Shi7, Wei Li8, Tingting Liang9, Xiaobing Chen10, Fang Wang11, Yuting Ding12, Yang Zhao13, Yongqian Shu14
1 Jiangsu Province Hospital, Nanjing City, China
2 The First Affiliated Hospital of Kunming Medical University, Kunming City, China
3 ?Maanshan People's Hospital, Maanshan City, China
4 Taizhou People's Hospital, Taizhou City, China
5 Jiang Provice Official Hospital, Nanjing City, China
6 Changzhou Wujin People's Hospital, Changzhou City, China
7 Suzhou Municipal Hospital, Suzhou City, China
8 The First Affiliated Hospital of Soochow University, Suzhou City, China
9 The first hospital of Jilin University, Jilin City, China
10 Henan Cancer Hospital , China, Zhengzhou City, China
11 Jiangsu Province Hospital, Nanjing City, China
12 Jiangsu Province Hospital, Nanjing City, China
13 Nanjing Medical University, Nanjing City, China
14 Jiangsu Province Hospital, Nanjing City, China

Background: Thrombocytopenia, defined as a peripheral blood platelet count below the normal range (typically <100×109/L), is a common complication of cancer treatment. The underlying pathophysiology is complex: chemotherapeutic agents, radiotherapy, certain targeted therapies, and immune checkpoint inhibitors can all impair platelet production. This decline in platelet count, whether resulting directly or indirectly from anticancer therapy, is collectively referred to as cancer therapy-induced thrombocytopenia (CTIT). According to the 2026 CSCO guidelines for the management of cancer therapy-induced thrombocytopenia, rhIL-11 is a Grade I recommendation, whereas Romiplostim is a Grade II recommendation. Against this background, this study aimed to evaluate the clinical efficacy and safety of romiplostim N01 compared with recombinant human interleukin-11 (rhIL-11) in patients with CTIT, thereby providing high-level evidence to guide the clinical management of CTIT.

Methods: A multicenter, randomized, open-label, prospective, controlled trial (NCT06759636) was conducted. A total of 94 patients were randomized to the experimental and control groups and included in the analysis. The intention-to-treat (ITT) population consisted of 49 patients in the experimental group (romiplostim N01) and 45 in the control group (rhIL-11). The full analysis set (FAS) comprised 49 patients in the experimental group and 39 in the control group. The experimental group received subcutaneous Romiplostim N01 at an initial dose of 3.0μg/kg weekly, with individualized dose titration for up to 4 weeks. The control group received rhIL-11 at 25–50μg/kg daily for 7–14 consecutive days. The primary endpoint was the median time to reach a platelet count of 100×109/L or an absolute increase of 50×109/L. Safety was evaluated according to the Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0). Statistical analyses were performed using R software and GraphPad Prism 10.0.

Results: The study enrolled 94 patients with solid tumors from 11 hospitals between March 2025 and April 2026, with platelet counts ranging from 10×109/L to 75×109/L. The two groups were well balanced in terms of demographic characteristics, clinicopathological features, and baseline laboratory parameters. For the primary endpoint analysis, the median time for platelet counts to reach 100×109/L or to increase by an absolute value of 50×109/L was 6 days (95% CI, 6.00–7.00) in the treatment group and 8 days (95% CI, 6.00–9.00) in the control group, in both the ITT and FAS (HR = 1.64, 95% CI 1.06–2.52; P = 0.010). The treatment group thus achieved a significantly shorter time to the primary endpoint than the control group. in patients with baseline platelet counts <50×109/L, the median time for platelet counts to increase to 100×109/L was 7.5 days (95% CI, 6.00–10.00) in the treatment group and 10.0 days (95% CI, 7.00–14.00) in the control group, in both the ITT and FAS (HR = 1.92, 95% CI 1.01–3.65). The one-week response rate was markedly higher in the experimental group (71.43% vs. 42.22%), accompanied by a higher peak platelet count. Regarding safety, the incidence of treatment-related adverse events (TRAEs) was substantially lower in the experimental group (10.2%) than in the control group (61.54%). No grade ≥3 TRAEs or serious adverse events (SAEs) occurred in the experimental arm, and no treatment discontinuations were necessitated by toxicity. In the control group, TRAEs were predominantly edema, fatigue, and pyrexia; treatment discontinuations due to toxicity, grade ≥3 adverse events, and SAEs were also observed (7.69%). Multivariable Cox proportional hazards regression analysis revealed that treatment with Romiplostim N01 was an independent predictor of a shorter time to the primary endpoint.

Conclusion: Romiplostim N01 demonstrated superior efficacy and a more favorable safety profile compared with rhIL-11 in the treatment of CTIT. It promoted rapid platelet recovery and improved early response rates with minimal toxicity, thereby supporting the uninterrupted delivery of antineoplastic therapy. These findings indicate that Romiplostim N01 represents a preferred therapeutic option for the clinical management of CTIT.

Xiaofeng Chen: No relevant conflicts of interest to declare.